Tni Biotech Inc (TNIB) 0.6900 $TNIB
TNI BioTech, Inc. Obtains Drug Approval For Sale of Low Dose Naltrexone (LDN) From Government of Malawi
PR Newswire - Tue May 06, 9:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) ("TNI BioTech"
, a biotechnology company focused on the development, marketing and distribution of opioid-related immunotherapies, today announced that effective as of April 16, 2014, it has successfully obtained approval from the Government of Malawi's drug regulatory authority, the Malawi Pharmacy, Medicines and Poisons Board, for the marketing and sale of Low Dose Naltrexone (LDN) in Malawi for the treatment of patients with cancer.
TNI BioTech, Inc. Announces Proposed Spin-Off of Cytocom, Inc.
PR Newswire - Thu May 01, 9:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or the "Company", a biopharmaceutical company focused on the development, marketing and distribution of opioid-related immunotherapies, announced that its board of directors has approved a plan to spin off its wholly-owned subsidiary, Cytocom, Inc. ("Cytocom", an entity established to operate TNIB's drug development business.
TNI BioTech, Inc. Announces Further Agreement on Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd.
PR Newswire - Wed Mar 26, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), today announced that it has signed a 'Supplementary Cooperation Agreement (the "Agreement" on New Drug Methionine-Enkephalin' with Hubei Qianjiang Pharmaceutical Co., Ltd. (a Chinese listed company, hereinafter referred to as "Qianjiang".
TNI BioTech, Inc. Granted Additional Patent for Methods for Inducing Sustained Immune Response of T-Cells
PR Newswire - Wed Mar 12, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy through the acquisition and licensing of late development stage compounds, today announced the U.S. Patent and Trademark Office (USPTO) has granted a key patent for IRT-101 (MENK) for inducing sustained immune response of T-Cells.
The Brewer Group Announces Strategic Partnership with TNI BioTech, Inc.
PR Newswire - Fri Mar 07, 9:00AM CST
The Brewer Group, Inc. ("TBG" a global investment advisory firm, today announced a new strategic partnership with TNI BioTech, Inc. ("TNIB" (OTCQB: TNIB), a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Through a variety of business development strategies including exclusive access to its extensive global reach, TBG will provide tailored services including investment banking advisory as well as government, investor relations and marketing support to TNIB in an effort to offer affordable treatment technologies to those in need for as low as $1.00 USD per day in numerous markets throughout the world.
TNI BioTech, Inc. Forms New Subsidiary, Cytocom Inc., to develop LDN and MENK
PR Newswire - Thu Mar 06, 9:00AM CST
TNI BioTech, Inc. (OTC: TNIB) announced today that it has formed a new subsidiary, Cytocom, Inc., for the purpose of developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).
TNI BIOTECH Announces SEC Clearance Of Form 10 Registration Statement And Clears Way To Upgrade To A Higher Exchange
PR Newswire - Tue Feb 11, 2:30PM CST
TNI BioTech Inc., (OTCQB:TNIB) a biotechnology company pioneering the development ofinnovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC" that the SEC has completed its review of the Company's Form 10 registration statement, effectively clearing all comments from the SEC.
TNI BioTech, Inc. Subsidiary Granted Certificate of Free Sale by Nicaraguan Minister of Health for Low Dose Naltrexone
Marketwire - Tue Dec 03, 7:16AM CST
TNI BioTech Inc (OTCQB: TNIB) today announced that the Nicaraguan Ministry of Health has granted a certificate of free sale to the company's wholly-owned subsidiary, TNI BioTech International Ltd., for TNI BioTech's Low Dose Naltrexone product (LDN) for the treatment of patients with autoimmune diseases HIV/AIDS, Crohn's Disease, Multiple Sclerosis and certain cancers.
Today's Small Cap Stocks in Focus - PFIE, AFFY and TNIB
ACCESSWIRE - Thu Nov 07, 5:37AM CST
Profire Energy, Inc. (OTC: PFIE), Affymax, Inc. (OTC: AFFY) and TNI BioTech, Inc. (PINK: TNIB) have been added to our watch list.
TNI BioTech, Inc: Clarification of Press Release Pursuant to Form 8-K
ACCESSWIRE - Fri Sep 13, 11:34AM CDT
BETHESDA, MD, September 13, 2013 - (ACCESSWIRE) - On September 11, 2013 a press release entitled TNI BioTech, Inc. (OTCQB: TNIB) Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants was circulated. It incorrectly stated that the company "received a capital investment of $1,360,625.00 from the conversion existing warrants by our shareholders. The Company believes that other warrant holders will convert and provide the company with additional capital between $250,000 to $500,000 in the coming month." The correct statement, as illustrated by the company's 8-K filed on September 12, 2013 should read:
TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants
Business Wire - Wed Sep 11, 5:00AM CDT
TNI BioTech, Inc. (OTCQB:TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN" for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed.
TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN
ACCESSWIRE - Wed Sep 04, 7:09AM CDT
BETHESDA, MD, September 4, 2013 - (Accesswire) - TNI BioTech, Inc. (OTCQB: TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN" for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed.
TNI BioTech Receives Meeting Minutes from FDA Type C Meeting on Naltrexone HCL for the treatment of Crohn's Disease
ACCESSWIRE - Wed Jul 24, 8:10AM CDT
BETHESDA, MD, July 24, 2013 - (eTeligis via ACCESSWIRE)- TNI BioTech, Inc. (OTCQB: TNIB) is pleased to announce that on July 17, 2013 the company received the official minutes from its recent Type C meeting held June 26, 2013 with the Division of Gastroenterology and Inborn Errors Products regarding the clinical and regulatory aspects of the proposed Phase III development program and future 505(b)(2) application for Low Dose Naltrexone (LDN) in the treatment of adults and pediatric patients with Crohn's Disease. TNI BioTech, Inc. also received official written responses regarding CMC and non-clinical aspects of the LDN development program.
FDA Grants TNI BioTech, Inc. an End of Phase II Meeting on August 20, 2013 to Discuss MENK® Phase III Study Design
ACCESSWIRE - Tue Jul 09, 8:24AM CDT
Bethesda, MD (eTeligis via ACCESSWIRE) - July 8, 2013 - TNI BioTech, Inc. (OTCQB: TNIB) announced today that the U.S. Food & Drug Administration (FDA) has agreed to an End of Phase II meeting on August 20, 2013 to discuss TNIB's clinical development program and Chemistry and Manufacturing Control (CMC) plans for MENK® in combination with gemcitabine in the treatment of pancreatic cancer. During the meeting, TNIB will discuss the proposed plans for a Phase III study, the FDA's requirements for the size of the safety population, and the adequacy of the completed preclinical studies that will support a marketing application. Once the meeting is complete, TNIB will report the outcome to the financial community in a timely fashion.
FDA Grants TNI BioTech, Inc. an End of Phase II Meeting on August 20, 2013 to Discuss MENK[R] Phase III Study Design
ACCESSWIRE - Tue Jul 09, 7:20AM CDT
Bethesda, MD, July 9, 2013 - (eTeligis via Accesswire) - TNI BioTech, Inc. (OTCQB: TNIB) announced today that the U.S. Food & Drug Administration (FDA) has agreed to an End of Phase II meeting on August 20, 2013 to discuss TNIB's clinical development program and Chemistry and Manufacturing Control (CMC) plans for MENK[R] in combination with gemcitabine in the treatment of pancreatic cancer. During the meeting, TNIB will discuss the proposed plans for a Phase III study, the FDA's requirements for the size of the safety population, and the adequacy of the completed preclinical studies that will support a marketing application. Once the meeting is complete, TNIB will report the outcome to the financial community in a timely fashion.
TNI BioTech, Inc., Concludes Type C Meeting at the FDA
ACCESSWIRE - Mon Jul 01, 9:26AM CDT
BETHESDA, Md - (Eteligis via Accesswire ) -- TNI BioTech, Inc. ("TNIB", the "Company" (OTCQB: TNIB) announced today that it has a Type C Meeting with the FDA in Washington, D.C., to review the Company's Development Program for its Phase III Drug Candidate, Naltrexone HCL [Low Dose Naltrexone (LDN) IRT-103
TNI BioTech, Inc. Announces Mandatory Exchange of Common Stock Certificates CUSIP Number 872608104 for New Stock Certificates with Active CUSIP 872608203
PR Newswire - Fri Jun 07, 11:34AM CDT
TNI BioTech, Inc. (TNIB, the "Company" (OTCQB: TNIB) announced today that effective as of the opening of business on Monday June 10, 2013, the Company will require the mandatory exchange of all existing common stock certificates issued with or under any prior CUSIP number for new stock certificates with the new CUSIP number 872608203.
TNI BioTech, Inc. Announces Death of Senior Vice President and Chief Medical Officer, Dr. Ronald Herberman
PR Newswire - Mon Jun 03, 7:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) announced today that Dr. Ronald Herberman, the Company's Senior Vice President and Chief Medical Officer, unexpectedly passed away over the weekend.
TNI BioTech, Inc. Obtains Drug Approval For Sale of Low Dose Naltrexone (LDN) From Government of Malawi
PR Newswire - Tue May 06, 9:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) ("TNI BioTech"
, a biotechnology company focused on the development, marketing and distribution of opioid-related immunotherapies, today announced that effective as of April 16, 2014, it has successfully obtained approval from the Government of Malawi's drug regulatory authority, the Malawi Pharmacy, Medicines and Poisons Board, for the marketing and sale of Low Dose Naltrexone (LDN) in Malawi for the treatment of patients with cancer. TNI BioTech, Inc. Announces Proposed Spin-Off of Cytocom, Inc.
PR Newswire - Thu May 01, 9:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or the "Company"
, a biopharmaceutical company focused on the development, marketing and distribution of opioid-related immunotherapies, announced that its board of directors has approved a plan to spin off its wholly-owned subsidiary, Cytocom, Inc. ("Cytocom", an entity established to operate TNIB's drug development business. TNI BioTech, Inc. Announces Further Agreement on Methionine-Enkephalin with Hubei Qianjiang Pharmaceutical Co., Ltd.
PR Newswire - Wed Mar 26, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), today announced that it has signed a 'Supplementary Cooperation Agreement (the "Agreement"
on New Drug Methionine-Enkephalin' with Hubei Qianjiang Pharmaceutical Co., Ltd. (a Chinese listed company, hereinafter referred to as "Qianjiang". TNI BioTech, Inc. Granted Additional Patent for Methods for Inducing Sustained Immune Response of T-Cells
PR Newswire - Wed Mar 12, 9:00AM CDT
TNI BioTech, Inc. (OTC: TNIB), a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy through the acquisition and licensing of late development stage compounds, today announced the U.S. Patent and Trademark Office (USPTO) has granted a key patent for IRT-101 (MENK) for inducing sustained immune response of T-Cells.
The Brewer Group Announces Strategic Partnership with TNI BioTech, Inc.
PR Newswire - Fri Mar 07, 9:00AM CST
The Brewer Group, Inc. ("TBG"
a global investment advisory firm, today announced a new strategic partnership with TNI BioTech, Inc. ("TNIB" (OTCQB: TNIB), a biotechnology company pioneering the development of innovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Through a variety of business development strategies including exclusive access to its extensive global reach, TBG will provide tailored services including investment banking advisory as well as government, investor relations and marketing support to TNIB in an effort to offer affordable treatment technologies to those in need for as low as $1.00 USD per day in numerous markets throughout the world. TNI BioTech, Inc. Forms New Subsidiary, Cytocom Inc., to develop LDN and MENK
PR Newswire - Thu Mar 06, 9:00AM CST
TNI BioTech, Inc. (OTC: TNIB) announced today that it has formed a new subsidiary, Cytocom, Inc., for the purpose of developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).
TNI BIOTECH Announces SEC Clearance Of Form 10 Registration Statement And Clears Way To Upgrade To A Higher Exchange
PR Newswire - Tue Feb 11, 2:30PM CST
TNI BioTech Inc., (OTCQB:TNIB) a biotechnology company pioneering the development ofinnovative therapies for autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system, today announced that it received notification from the U.S. Securities and Exchange Commission ("SEC"
that the SEC has completed its review of the Company's Form 10 registration statement, effectively clearing all comments from the SEC. TNI BioTech, Inc. Subsidiary Granted Certificate of Free Sale by Nicaraguan Minister of Health for Low Dose Naltrexone
Marketwire - Tue Dec 03, 7:16AM CST
TNI BioTech Inc (OTCQB: TNIB) today announced that the Nicaraguan Ministry of Health has granted a certificate of free sale to the company's wholly-owned subsidiary, TNI BioTech International Ltd., for TNI BioTech's Low Dose Naltrexone product (LDN) for the treatment of patients with autoimmune diseases HIV/AIDS, Crohn's Disease, Multiple Sclerosis and certain cancers.
Today's Small Cap Stocks in Focus - PFIE, AFFY and TNIB
ACCESSWIRE - Thu Nov 07, 5:37AM CST
Profire Energy, Inc. (OTC: PFIE), Affymax, Inc. (OTC: AFFY) and TNI BioTech, Inc. (PINK: TNIB) have been added to our watch list.
TNI BioTech, Inc: Clarification of Press Release Pursuant to Form 8-K
ACCESSWIRE - Fri Sep 13, 11:34AM CDT
BETHESDA, MD, September 13, 2013 - (ACCESSWIRE) - On September 11, 2013 a press release entitled TNI BioTech, Inc. (OTCQB: TNIB) Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants was circulated. It incorrectly stated that the company "received a capital investment of $1,360,625.00 from the conversion existing warrants by our shareholders. The Company believes that other warrant holders will convert and provide the company with additional capital between $250,000 to $500,000 in the coming month." The correct statement, as illustrated by the company's 8-K filed on September 12, 2013 should read:
TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN and receives $1,500,000 in funding from the exercise of warrants
Business Wire - Wed Sep 11, 5:00AM CDT
TNI BioTech, Inc. (OTCQB:TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN"
for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed. TNI BioTech, Inc. Signs Manufacturing Agreement for IRT-103[TM] LDN
ACCESSWIRE - Wed Sep 04, 7:09AM CDT
BETHESDA, MD, September 4, 2013 - (Accesswire) - TNI BioTech, Inc. (OTCQB: TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone ("LDN"
for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases by combating these fatal diseases through the activation and modulation of the body's immune system. Under the agreement, TNIB and Laboratorios Ramos are responsible for the technology transfer, under a manufacturing agreement, and commercial production of LDN at the Laboratorios Ramos processing facility. Laboratorios Ramos operates "under the principles of the ICH" for cGMP and currently produces commercial products for sale in Nicaragua. The financial terms of the agreement have not been disclosed. TNI BioTech Receives Meeting Minutes from FDA Type C Meeting on Naltrexone HCL for the treatment of Crohn's Disease
ACCESSWIRE - Wed Jul 24, 8:10AM CDT
BETHESDA, MD, July 24, 2013 - (eTeligis via ACCESSWIRE)- TNI BioTech, Inc. (OTCQB: TNIB) is pleased to announce that on July 17, 2013 the company received the official minutes from its recent Type C meeting held June 26, 2013 with the Division of Gastroenterology and Inborn Errors Products regarding the clinical and regulatory aspects of the proposed Phase III development program and future 505(b)(2) application for Low Dose Naltrexone (LDN) in the treatment of adults and pediatric patients with Crohn's Disease. TNI BioTech, Inc. also received official written responses regarding CMC and non-clinical aspects of the LDN development program.
FDA Grants TNI BioTech, Inc. an End of Phase II Meeting on August 20, 2013 to Discuss MENK® Phase III Study Design
ACCESSWIRE - Tue Jul 09, 8:24AM CDT
Bethesda, MD (eTeligis via ACCESSWIRE) - July 8, 2013 - TNI BioTech, Inc. (OTCQB: TNIB) announced today that the U.S. Food & Drug Administration (FDA) has agreed to an End of Phase II meeting on August 20, 2013 to discuss TNIB's clinical development program and Chemistry and Manufacturing Control (CMC) plans for MENK® in combination with gemcitabine in the treatment of pancreatic cancer. During the meeting, TNIB will discuss the proposed plans for a Phase III study, the FDA's requirements for the size of the safety population, and the adequacy of the completed preclinical studies that will support a marketing application. Once the meeting is complete, TNIB will report the outcome to the financial community in a timely fashion.
FDA Grants TNI BioTech, Inc. an End of Phase II Meeting on August 20, 2013 to Discuss MENK[R] Phase III Study Design
ACCESSWIRE - Tue Jul 09, 7:20AM CDT
Bethesda, MD, July 9, 2013 - (eTeligis via Accesswire) - TNI BioTech, Inc. (OTCQB: TNIB) announced today that the U.S. Food & Drug Administration (FDA) has agreed to an End of Phase II meeting on August 20, 2013 to discuss TNIB's clinical development program and Chemistry and Manufacturing Control (CMC) plans for MENK[R] in combination with gemcitabine in the treatment of pancreatic cancer. During the meeting, TNIB will discuss the proposed plans for a Phase III study, the FDA's requirements for the size of the safety population, and the adequacy of the completed preclinical studies that will support a marketing application. Once the meeting is complete, TNIB will report the outcome to the financial community in a timely fashion.
TNI BioTech, Inc., Concludes Type C Meeting at the FDA
ACCESSWIRE - Mon Jul 01, 9:26AM CDT
BETHESDA, Md - (Eteligis via Accesswire ) -- TNI BioTech, Inc. ("TNIB", the "Company"
(OTCQB: TNIB) announced today that it has a Type C Meeting with the FDA in Washington, D.C., to review the Company's Development Program for its Phase III Drug Candidate, Naltrexone HCL [Low Dose Naltrexone (LDN) IRT-103 TNI BioTech, Inc. Announces Mandatory Exchange of Common Stock Certificates CUSIP Number 872608104 for New Stock Certificates with Active CUSIP 872608203
PR Newswire - Fri Jun 07, 11:34AM CDT
TNI BioTech, Inc. (TNIB, the "Company"
(OTCQB: TNIB) announced today that effective as of the opening of business on Monday June 10, 2013, the Company will require the mandatory exchange of all existing common stock certificates issued with or under any prior CUSIP number for new stock certificates with the new CUSIP number 872608203. TNI BioTech, Inc. Announces Death of Senior Vice President and Chief Medical Officer, Dr. Ronald Herberman
PR Newswire - Mon Jun 03, 7:00AM CDT
TNI BioTech, Inc. (OTCQB: TNIB) announced today that Dr. Ronald Herberman, the Company's Senior Vice President and Chief Medical Officer, unexpectedly passed away over the weekend.
